Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 189.02B | 176.86B | 200.34B | 193.82B | 187.22B |
Gross Profit | 56.35B | 54.32B | 62.63B | 66.65B | 72.43B |
EBITDA | 36.20B | 36.87B | 33.93B | -18.71B | 37.25B |
Net Income | 22.94B | 13.70B | 12.67B | -28.27B | 12.34B |
Balance Sheet | |||||
Total Assets | 348.83B | 382.02B | 364.17B | 349.50B | 393.34B |
Cash, Cash Equivalents and Short-Term Investments | 38.78B | 26.54B | 33.26B | 47.86B | 54.27B |
Total Debt | 91.34B | 82.89B | 73.13B | 66.75B | 71.85B |
Total Liabilities | 164.01B | 163.99B | 151.43B | 149.42B | 152.59B |
Stockholders Equity | 184.82B | 212.66B | 201.64B | 190.07B | 218.28B |
Cash Flow | |||||
Free Cash Flow | 7.28B | -1.50B | -14.12B | 10.97B | 10.73B |
Operating Cash Flow | 27.85B | 23.15B | 13.03B | 34.31B | 31.86B |
Investing Cash Flow | 6.48B | -23.11B | -27.13B | -30.39B | -21.79B |
Financing Cash Flow | -32.70B | 2.36B | -1.27B | -11.26B | -11.99B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥147.30B | 7.76 | 11.38% | 2.67% | 13.89% | 17.38% | |
77 Outperform | ¥80.33B | 9.65 | 0.66% | 8.83% | 70.61% | ||
76 Outperform | ¥64.64B | 13.50 | 2.06% | 2.06% | -32.48% | ||
75 Outperform | $164.61B | 14.70 | 5.47% | 2.23% | 16.87% | 11.24% | |
69 Neutral | ¥181.27B | 18.88 | 2.96% | -3.69% | -18.73% | ||
65 Neutral | ¥177.54B | 31.98 | 4.56% | 1.90% | 9.56% | 5.09% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 17.09% | 1.64% |
Sawai Group Holdings Co., Ltd. announced the issuance of 19,920 new shares as restricted share compensation, aimed at aligning the interests of directors and officers with the company’s long-term performance goals. This initiative is designed to motivate key personnel by linking their compensation to the company’s share price and performance metrics, with a minor dilutive effect of 0.017% on existing shares.
The most recent analyst rating on (JP:4887) stock is a Buy with a Yen3000.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. announced that its subsidiary, Sawai Pharmaceutical Co., Ltd., has filed a final appeal with the Supreme Court following an unfavorable ruling by the IP High Court in a patent infringement lawsuit concerning the use patent of Nalfurafine. The company is reviewing the potential financial impact of this legal development and will inform stakeholders of any significant updates.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. announced a correction to its consolidated financial results for the fiscal year ended March 31, 2025, due to a provision for loss on litigation amounting to JPY 16,757 million. This adjustment significantly impacted the company’s financial statements, reflecting a decrease in operating profit and profit before tax, highlighting challenges in their financial performance and potential implications for stakeholders.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. announced that the Intellectual Property High Court of Japan ruled against its subsidiary, Sawai Pharmaceutical Co., Ltd., in a patent infringement lawsuit concerning Nalfurafine Hydrochloride OD Tablets. The court’s decision requires Sawai Pharmaceutical to pay damages amounting to over 14 billion yen. The company is assessing the financial impact and plans to appeal the decision, indicating potential implications for its financial statements and legal strategy.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. has revised its corporate officer remuneration plan to include a Restricted Stock Compensation Plan and a Performance-linked Restricted Stock Compensation Plan. This move is aimed at aligning the interests of its directors with shareholders by tying compensation to the company’s medium- to long-term performance and stock value. The new plan will replace the existing stock acquisition rights and requires shareholder approval at the upcoming General Meeting. This strategic shift is expected to strengthen the company’s market positioning by incentivizing directors to enhance corporate performance and value.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. has announced a proposal to amend its Articles of Incorporation, transitioning to a company with an Audit & Supervisory Committee. This change, subject to shareholder approval, aims to enhance corporate governance and adapt to external changes, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. announced it will receive a significant dividend of 19,268 million yen from its subsidiary, Sawai Pharmaceutical Co., Ltd., which will be recorded in its non-consolidated financial statements for the fiscal year ending March 31, 2026. This transaction will not affect the consolidated financial statements, indicating a strategic financial maneuver to optimize internal financial structuring without altering the overall financial outlook for stakeholders.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. announced changes in its board of directors as part of its transition to a company with an Audit and Supervisory Committee. These changes, which include new director nominations and retirements, are set to be approved at the upcoming Annual General Meeting of Shareholders, potentially impacting the company’s governance structure and oversight.
The most recent analyst rating on (JP:4887) stock is a Buy with a Yen2800.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings reported its consolidated financial results for the fiscal year ending March 31, 2025, revealing a significant increase in profit attributable to owners of the parent by 67.5% year-on-year, despite a decrease in total comprehensive income by 14.4%. The company also noted the classification of its U.S. business as a discontinued operation and executed a 3-for-1 stock split effective October 1, 2024, impacting earnings per share calculations. These strategic moves and financial outcomes reflect Sawai’s efforts to streamline operations and enhance shareholder value.
The most recent analyst rating on (JP:4887) stock is a Buy with a Yen2800.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
Sawai Group Holdings Co., Ltd. has announced the retirement of 16,016,600 of its own shares, representing 12.2% of the total shares issued before retirement. This strategic move, scheduled for April 30, 2025, aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation.